




ATTORNEY DOCKET APPLICATION NO. INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98) 23164-1003 08/853,292 APPLICANT(S) Tovey, Michael G. FILING DATE SHEET 1 OF 2 **GROUP** May 9, 1997 1801 1646 **U.S. PATENT DOCUMENTS** t EX'R U.S. CLASS/ FILING DATE REF. # INITIAL PATENT NUMBER DATE (MO/YR) NAME **SUBCLASS** (If appropriate) Α 4,605,555 8/86 Sato et al 424/85 В 4,820,514 4/89 **Cummins** 424/85.4 С 5,019,382 5/91 Cummins, Jr. 424/85.4 D 5,215,741 6/93 Young et al. 424/85.7 Е 5,286,748 2/94 Eby, III 514/494 FOREIGN PATENT DOCUMENTS † EX'R TRANSLATION INITIAL REF. # (YES/NO) F CA 1,320,905 8/93 Canada yes OTHER DOCUMENTS † EX'R INITIAL REF. # CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.) Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon-γ in Asthmatic Airways", J. Allergy Clin. Immunol. 95:133-135 (1995). Brod et al., "Oral Administration of IFN- α is Superior to Subcutaneous Administration of IFN- α in the Н Suppression of Chronic...", Journal of Autoimmunity 9:11-20 (1996). Douglas et al., "Prophylactic Efficacy of Intranasal Alpha2-Interferon Against Rhinovirus Infections in the Family Setting" 314: 65-70 (1986). Hayden et al., "Intranasal Interferon $\alpha 2$ for Prevention of Rhinovirus Infection and Illness", Journal of Infectious Diseases 148:543-550 (1983). Hayden et al., "Human Tolerance and Histopathologic Effects of Long Term Administration of Intranasal Interferon-α2", Journal of Infectious Diseases 148:914-921 (1983). Hayden et al., "Prevention of Natural colds by Contact Prophylaxis with Intranasal Alpha₂-Interferon", New England Journal Of Medicine 314:71-75 (1986). Hayden et al., "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A M Interferon", Journal of Infectious Diseases 156:64-72 (1987). lida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) infections in mice", Vaccine 7:229-233 (1989). Matsuzawa et al., "Protective Effect of Mucosal Administration of Recombinant Human Macrophage Colony-Stimulating Factor...", Vaccine 15:85-89 (1997). Moore et al., "Inflammatory Markers in Bronchoalveolar Lavage Fluid of Standardbred Racehorses with Inflammatory...", Equine Veterinary Journal 29:142-147 (1997). Oehling et al., "Suppresion of the Immune System by Oral Glucocorticoid Therapy in Bronchial Asthma". Allergy 52:144-154.

> DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800

9/24/58





			7.0
M	R_	Samo et al., "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers", Journal of Infectious Diseases 148:535-542 (1983).	
-	S/	Samo et al., "Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers. II.", Journal of Infectious Diseases 150:181-188 (1984).	
	Т	Soos et al., Oral Feeding of Interferon τ Can Prevent the Acute and Chronic Relapsing Forms of Experimental Allergic Encephalomyelitis", <i>Journal of Neuroimmunology</i> 75 :43-50 (1997).	
	U /	Vriesendorp et al., "Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis", Autoimmunity 24:157-165 (1996).	
Ŋ	٧,	Zielinska et al., "Comparison of the Long-Term Effects of Treatment with Oral and Parenteral", Archivum Immunologiae et Therapiae Experimentalis 44:359-366 (1996).	
EXAMINER'S SIGNATURE DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800			DATE CONSIDERED 9/24/58
† EXAMI	NER: Initi	al if reference is considered, whether or not citation is in	conformance with MPEP 609. Line through citation if not in

conformance and not considered. Include copy of this form in next communication to applicant.

